Interviews

New study signals ctDNA MRD clearance and 90% drops predict better gastroesophageal cancer outcomes, fueling calls for prospective trials.

Erica Pimenta, MD, PhD, discusses how the IGF-1 and GLP-1 pathways could potentially be targets in dedifferentiated liposarcoma.

Digital twin modeling plus metabolomics predicts which drugs can starve glioblastoma, enabling faster, personalized treatment testing.

Luciano Costa, MD, PhD, discussed why the lack of high-grade cytokine release syndrome in the MajesTEC-3 trial should encourage the use of teclistamab.

Frontline antibody-drug conjugates boost progression-free survival in metastatic triple-negative breast cancer, showing early overall survival gains and expanding options.

Dr. Antoni Vilaseca Cabo discusses using an intravesical drug delivery system to continuously administer the FGFR inhibitor erdafitinib directly into the bladder, marking the first mutation-directed therapy for non-muscle invasive bladder cancer that offers patients an oncologically beneficial and bladder-sparing option with minimal toxicity.

A discussion with the patient about the importance of bone health when treated with androgen-deprivation therapy (ADT) should occur early in the treatment plan.

In an interview, Paul G. Richardson, MD, gave an overview of the ways that CELMoDs are poised to impact the landscape of multiple myeloma treatment at various stages of disease treatment.

MRD testing personalizes diffuse large B‑cell lymphoma therapy—shorten chemo for early responders and flag high‑risk patients for targeted add‑ons.

New HER2+ breast cancer trials refine chemo and antibody use—cutting toxicity with de‑escalation, while escalating high‑risk patients with T‑DXd.

Blood biomarkers reveal which glioblastoma patients respond to Delta-24-RGD oncolytic virus plus IFN-γ, guiding personalized dosing and survival.

Luciano Costa, MD, PhD, discusses the how the MajesTEC-3 trial's 83% improvement in PFS contributed to a 3-month turnaround to FDA approval.

MRD testing promises sharper DLBCL response tracking than PET scans, cutting false positives, biopsies, and guiding therapy as trials catch up.

MRD testing in lymphoma grows fast, but varying assays and limited guidelines leave clinicians guessing; trials and standards clarify care.

Sagar Lonial, MD, discusses the expanding potential uses of cereblon E3 ligase modulators (CELMoDs) in combination with T-cell redirection therapies in multiple myeloma.

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance.

Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates.

Denileukin diftitox brings a new systemic option for relapsed CTCL, killing tumor cells and Tregs to boost immunity and expand EU access.

Althopugh current prostate cancer biomarkers have improved the detection of clinically significant disease (Gleason Grade Group 2+), they fail to distinguish between high-grade cancer and genuinely lethal cancer, potentially leading to overtreatment and underscoring the need for next-generation tools that identify patients at true mortality risk.

In an interview, Vincent Ma, MD, explores the clinical utility of circulating tumor DNA dynamics to assess early outcomes in patients with melanoma.

Natalie Berger, MD, weighed the biggest hurdles she witnesses in HPV vaccination and screening adherences.

ctDNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes.

Breast cancer care shifts fast: ADCs reach HER2-low, neoadjuvant regimens evolve, and ctDNA MRD testing sparks 2026’s debate.

In this interview, Sagar Lonial, MD, discusses the EXCALIBER-RRMM trial design and the potential role of iberdomide in the evolving therapeutic landscape of multiple myeloma.

David R. Wise, MD, PhD, discusses the use of gotistobart, a next-generation CTLA-4 targeting antibody, in prostate cancer.

ctDNA MRD monitoring may augment scans and tumor markers, enabling earlier detection of gastroesophageal cancer recurrence, especially hard-to-image peritoneal relapse.

Vincent Ma, MD, discusses a study evaluating circulating tumor DNA early in treatment of metastatic melanoma using immune checkpoint inhibitors.